Key Highlights

  • Net income was USD 26.3 million, or USD 0.32 per diluted share, in the third quarter of 2026, against USD 13.9 million, or USD 0.15, a year earlier.
  • Revenue rose 8.9% to USD 341.3 million, with fertility benefit services at USD 223.4 million and pharmacy benefit services at USD 117.9 million.
  • Adjusted Earnings reached USD 0.52 per diluted share versus USD 0.45, while adjusted EBITDA rose 6.3% to USD 58.4 million at a 17.1% margin.
  • Management raised the midpoint of 2026 guidance, now projecting Revenue of USD 1.365 billion to USD 1.385 billion and adjusted EBITDA of USD 235.0 million to USD 240.0 million.

Profit Doubles as Gross Margin Widens

Progyny (NASDAQ:PGNY) announced third-quarter results on November 4, 2026. GAAP Net Income was USD 26.3 million, or USD 0.32 per diluted share, compared with USD 13.9 million, or USD 0.15, in the prior-year period. The company tied the gain to higher Gross Profit and lower stock-based compensation, partly offset by lower interest and other income. Gross profit rose 15% to USD 83.7 million, lifting gross margin to 24.5% from 23.2%, which management attributed to efficiencies in delivering care management services. Revenue growth came from more clients and covered lives, with average members of 7,176,000 against 6,757,000 a year earlier. Net cash from Operating Activities was USD 56.6 million, up from USD 50.7 million.

Record Selling Season Sets Up 2027

Progyny provides fertility and family building benefits to employers. It said its latest selling season added a record 1.3 million new covered lives and more than 85 new clients, with near 100% retention for 2027 and Demand to expand coverage into pregnancy, parenting and menopause support. The company had 607 fertility clients at September 30, 2026, versus 553 a year earlier. Most new lives are expected to go live in the first quarter of 2027, and once all are live it anticipates more than 660 clients and about 8.3 million covered lives. Utilization for all members was 0.56% in the quarter against 0.54%, and assisted reproductive treatment cycles reached 16,723 versus 15,981.

Buybacks, Cash and Fourth-Quarter Guidance

The company repurchased nearly 3 million shares for USD 82.7 million in the quarter, and about USD 51 million remains under its May 2026 authorization. Cash and marketable securities were USD 195.6 million, down USD 41.3 million from June 30, 2026, with no Debt and an undrawn USD 200 million revolver. Full-year 2026 net income guidance is USD 107.0 million to USD 110.6 million, or USD 1.30 to USD 1.35 per diluted share. For the fourth quarter, it projects revenue of USD 344.7 million to USD 364.7 million and adjusted EBITDA of USD 57.9 million to USD 62.9 million. Adjusted EBITDA margin slipped from 17.5% as planned platform investments weighed, so profit growth rests on gross margin gains and engagement staying in line with expectations.

Where Things Stand

Net income nearly doubled because gross profit grew faster than costs, with lower stock-based compensation helping the GAAP figure. Progyny (NASDAQ:PGNY) grew revenue 8.9%, widened gross margin and raised its guidance midpoint, while the adjusted EBITDA margin eased slightly on platform spending. The company also said member activity remained healthy as the fourth quarter began. Next markers are fourth-quarter results, the first-quarter 2027 go-live of new clients, further Buybacks and 2027 guidance, which the company said it will provide with year-end results in February.